RNS re breast cancer20 Jul 2020 08:14
Angle PLC Study: Parsortix use in metastatic breast cancer
Source: UK Regulatory (RNS & others)
TIDMAGL
RNS Number : 4029T
Angle PLC
20 July 2020
For immediate release 20 July 2020
ANGLE plc ("the Company")
RESEARCH STUDY INVESTIGATES USE OF PARSORTIX LIQUID BIOPSY FOR METASTATIC BREAST CANCER PATIENTS
Pilot study compared Parsortix liquid biopsy to tissue biopsy of a metastatic site
Potential actionable therapeutic targets were found in the Parsortix liquid biopsy that were missed in the tissue biopsy of a single metastatic site
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is delighted to announce that University of Southern California (USC) has published peer-reviewed results of new work undertaken in metastatic breast cancer (MBC) highlighting key advantages of a Parsortix liquid biopsy compared to standard of care tissue biopsy. In addition to the known advantages of a non-invasive, repeatable, low cost procedure, USC showed that potential actionable therapeutic targets were found in the Parsortix liquid biopsy that were missed in the tissue biopsy of a single metastatic site.
The research investigated concordance between cancer cells obtained from the blood test (CTCs harvested by Parsortix) and cancer cells obtained from the metastatic tissue biopsy across 4,600 medically relevant genes and demonstrated that the use of single-site metastatic tumour biopsy, which is standard of care under the NCCN US national cancer guidelines, is unlikely to provide complete insight into tumour mutational status. Tissue biopsy is also limited by the quality, quantity and availability of tumour tissue. The study concluded that medically significant mutations may be found in the CTCs that are not expressed in the metastatic tissue biopsy. 51 actionable genes were identified in the CTCs including the 39 most frequently mutated genes in metastatic breast cancer.
This study demonstrates key capabilities of Parsortix for metastatic breast cancer, which is the area of focus for ANGLE's FDA submission currently in preparation with the aim of submission later this quarter (Q3 CY20).
The research has been published as a peer-reviewed publication in the International Journal of Molecular Sciences and may be accessed via https://angleplc.com/library/publications/ .
Julie Lang, Associate Professor at the Keck School of Medicine of the University of Southern California, commented:
"This study highlights both practical advantages of the Parsortix liquid biopsy in allowing non-invasive repeat biopsies in metastatic breast cancer and technical advantages in identifying actionable therapeutic targets that may be missed when relying on a single site tissue biopsy."
ANGLE Founder and Chief Executive, Andrew Newland, commented:
"The demonstration of advanced gene expression analysis techniques on CTCs harvested by Parsortix highlights an important potential clinical use of the Parsortix sys
Sign In
Follow the stocks
